Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

NCT01968486 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Myopia, Degenerative

Interventions

DRUG: PDT standard fluence, ranibizumab
DRUG: PDT reduced fluence, ranibizumab
DRUG: ranibizumab

Sponsor

University of Campania Luigi Vanvitelli